0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.221.22. Please contact the publisher to request reinstatement.
Original Article |

Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults:  A Propensity Score–Adjusted Analysis of 9 Years' Data FREE

Sebastian Schneeweiss, MD, ScD; Amanda R. Patrick, MS; Daniel H. Solomon, MD, MPH; Jyotsna Mehta, MS; Colin Dormuth, MA, MS, ScD; Matthew Miller, MD, ScD; Jennifer C. Lee, BS; Philip S. Wang, MD, DrPH
[+] Author Affiliations

Author Affiliations: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School (Drs Schneeweiss, Solomon, and Wang and Mss Patrick, Mehta, and Lee) and Harvard Injury Control Research Center, Department of Health Policy and Management, Harvard School of Public Health (Dr Miller), Boston, Massachusetts; Therapeutics Initiative, Department of Anesthesia, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (Dr Dormuth); and National Institute of Mental Health, Bethesda, Maryland (Dr Miller).


Arch Gen Psychiatry. 2010;67(5):497-506. doi:10.1001/archgenpsychiatry.2010.39.
Text Size: A A A
Published online

Context  A US Food and Drug Administration advisory has warned that antidepressants may be associated with an increased risk of suicidal thoughts and behaviors in adolescents. This prompted a meta-analysis of trials in adults that found no overall increase in risk, but individual agents could not be studied.

Objective  To assess the risk of suicide and suicide attempts associated with individual antidepressant agents.

Design  Cohort study of incident users of antidepressant agents.

Setting  Population-based health care utilization data of all residents of British Columbia, Canada, aged 18 years and older between January 1, 1997, and December 31, 2005.

Patients  British Columbia residents who had antidepressant therapy initiated and had a recorded diagnosis of depression.

Intervention  Initiation of various antidepressant medications.

Main Outcome Measures  Combined suicide death or hospitalization due to self-harm.

Results  In a population of 287 543 adults aged 18 years and older with antidepressant therapy initiated, we observed outcome rates ranging from 4.41/1000 person-years to 9.09/1000 person-years. Most events occurred in the first 6 months after treatment initiation. After extensive propensity score adjustment, we found no clinically meaningful variation in the risk of suicide and suicide attempt between antidepressant agents compared with fluoxetine hydrochloride initiation: citalopram hydrobromide, hazard ratio = 1.00 (95% confidence interval, 0.63-1.57); fluvoxamine maleate, hazard ratio = 0.98 (95% confidence interval, 0.63-1.51); paroxetine hydrochloride, hazard ratio = 1.02 (95% confidence interval, 0.77-1.35); and sertraline hydrochloride, hazard ratio = 0.75 (95% confidence interval, 0.53-1.05). Compared with selective serotonin reuptake inhibitors as a drug class, other classes including serotonin-norepinephrine reuptake inhibitors, tricyclic agents, and other newer and atypical agents had a similar risk. Restriction to patients with no antidepressant use in the past 3 years further reduced apparent differences between groups.

Conclusions  Our finding of equal event rates across antidepressant agents supports the US Food and Drug Administration's decision to treat all antidepressants alike in their advisory. Treatment decisions should be based on efficacy, and clinicians should be vigilant in monitoring after initiating therapy with any antidepressant agent.

Figures in this Article

Despite the widespread use of antidepressant medications, particularly selective serotonin reuptake inhibitors (SSRIs), there is inconsistent evidence that growth in antidepressant use has reduced the prevalence of suicidal ideation or suicide attempts during the past decade.13 In October 2004, the US Food and Drug Administration issued an advisory that antidepressants may be associated with an increased risk of suicidal thoughts and behaviors in children and adolescents.4 These warnings were prompted by a meta-analysis of all available randomized trials of antidepressants in this age group, in which patients randomized to antidepressants had nearly twice the rate of suicidal ideation or behavior relative to those given placebo.5 These concerns prompted the US Food and Drug Administration to undertake a reanalysis of all its available antidepressant trials in adults as well. This meta-analysis and several subsequent analyses of short-term trials found no increased risk of suicidality in adult antidepressant users.69 However, the interpretation of this meta-analysis is limited by a number of factors including the brief duration of trials, few suicide attempts and almost no completed suicides, varying definitions of suicidality, noncomparable doses, and heterogeneous patient mixes.

Nonrandomized studies comparing users of different antidepressant classes—SSRIs, tricyclic agents (TCAs), serotonin-norepinephrine reuptake inhibitors,1012 or any antidepressant users vs nonusers13—have reported small or no differences in suicides and suicide attempts. However, serious questions remain whether these studies had adequate statistical power or were adequately controlled for prescribing biases caused by preferential avoidance of TCAs in patients at high risk. A cohort study in the General Practice Research Database found higher rates of suicide attempts in venlafaxine hydrochloride users compared with SSRI and TCA users but also observed a higher burden of suicide risk factors in venlafaxine users, raising the possibility of preferential prescribing in high-risk patients and residual confounding.14 A nested case-control study in residents of Ontario, Canada, aged 66 years and older found that SSRIs were associated with a nearly 5-fold increased risk of suicide during the first month of treatment compared with other antidepressants, but it found no difference between classes during subsequent periods.15 The investigators also observed a higher risk of violent suicide among SSRI users. However, a study using postmortem data found that a lower proportion of suicides was violent among SSRI users than among non–antidepressant users.16

While raising important concerns, the US Food and Drug Administration's meta-analyses and advisories have not provided patients, clinicians, or policy makers with adequate guidance on the treatment decisions they face, and nonrandomized studies face criticism for channeling bias. In the current study, we sought to address whether the risk of suicide is equal across antidepressant classes and agents after adjustment for selection factors—or whether there are particular regimens with safety advantages that should be prescribed preferentially in adult populations.

PATIENTS AND DATA SOURCE

We conducted a cohort study of all residents of British Columbia, Canada, aged 18 years and older who initiated use of an antidepressant medication between January 1, 1997, and December 31, 2005. Initiation was defined as filling an antidepressant prescription without having filled one in the preceding year. We considered only the first treatment episode during the study period for each patient for the analysis. We required evidence of depression as indicated by a diagnosis of depression recorded during 2 office visits or as a hospital discharge diagnosis during the 6 months prior to through 2 months after the initiation date (eTable 1). Depressed episodes of an existing bipolar disorder did not qualify for study entrance. We allowed subjects with diagnoses following the initiation date to be included in the cohort because some health care practitioners may prescribe an antidepressant as part of diagnosing the condition, in which case the diagnosis might follow the prescription. To ensure complete ascertainment of prior drug use, we required that subjects be residents of British Columbia as evidenced by being enrolled in the provincial Medical Services Plan during the year prior to initiation. Bupropion hydrochloride was not considered owing to its potential use for smoking cessation, and escitalopram oxalate was not considered because it was not marketed until December 2004, near the end of the study period.

The PharmaNet database used to identify antidepressant initiators includes the name, dose, and dispensed quantity for all prescription drugs dispensed in British Columbia pharmacies. This information is entered by pharmacists via a provincewide network that assures minimal underreporting and misclassification17 and is recorded for all dispensings independent of the payer. The British Columbia Ministry of Health Services also maintains linkable data on all physician services and hospitalizations for all persons in its publicly funded health care system. Up to 25 diagnoses for hospital discharges and 1 diagnosis for each medical service are recorded, with good specificity and completeness.18 These administrative data were further linked to vital statistics data that include information on cause of death, including suicide.

Because all British Columbia residents are covered for all medical services by the provincial Medical Services Plan except for a small number of federal employees and because drug dispensings are recorded for all dispensed prescription medications regardless of payer, the study sample is representative of British Columbia's adult population (about 3 million in 2005). All low-income residents, most elderly residents, and most other residents have drug insurance, with varying degrees of coverage.19

ANTIDEPRESSANT MEDICATION EXPOSURE

Antidepressant medications were classified into the following groups: SSRIs, including citalopram hydrobromide, fluoxetine hydrochloride, fluvoxamine maleate, paroxetine hydrochloride, and sertraline hydrochloride; serotonin-norepi nephrine reuptake inhibitors, including venlafaxine; TCAs, including amitriptyline hydrochloride, amoxapine, clomipramine hydrochloride, desipramine hydrochloride, doxepin hydrochloride, imipramine hydrochloride, maprotiline hydrochloride, nortriptyline hydrochloride, protriptyline hydrochloride, and trimipramine maleate; other newer and atypical agents, including mirtazapine, nefazodone hydrochloride, and trazodone hydrochloride; and monoamine oxidase inhibitors, including moclobemide, phenelzine sulfate, and tranylcypromine sulfate. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, was not marketed in Canada during the study period.

Exposure status was assigned based on the initiated medication, and follow-up began on the initiation date. We determined the availability of antidepressant supply for each patient day by stringing together consecutive antidepressant dispensings for each patient based on dispensing dates and reported “days' supply.”20 When a dispensing occurred before the previous dispensing should have run out, use of the new dispensing was assumed to begin the day after the end of the old dispensing. Each patient's exposure risk window ended when the subject had been without antidepressant supply for 14 days. We routinely assess the plausibility of recorded days' supply relative to quantity dispensed and recommended dosing, and we have found this information to be accurate.21 Sensitivity analyses were conducted to assess the effect of stacking prescriptions. While it is possible that some patients fill prescriptions without actually taking the medication, the patient cost-sharing requirements in British Columbia are likely to reduce the frequency with which this occurs, and prior studies have demonstrated good correspondence between pharmacy records and self-reported prescription drug use.22,23

Patients were censored at the date of the end of their exposure risk window, switching to or treatment augmentation with another antidepressant medication, emigration from the province, occurrence of a study outcome, death, or the end of the study period or the end of 1 year, whichever came first. While patients could have multiple treatment episodes, we included only the first in our analysis.

STUDY END POINTS

Study outcomes included attempted and completed suicide. Suicide attempt was defined as a hospitalization with an International Classification of Diseases, Ninth Revision (ICD-9)24 external cause of injury code (E-code) of deliberate self-harm (E950.x-E958.x). Completed suicides were deaths with an ICD-9 E-code of E950.x-E958.x or an International Statistical Classification of Diseases, 10th Revision (ICD-10)25 diagnosis code of X60-X84 listed as the cause of death. These were identified using a vital statistics file that includes cause of death as reported on the patient's death certificate. Violent suicide attempts (ICD-9 E-codes) and completed suicides (ICD-10 X-codes) were defined as those involving the following: hanging (E953.0; X70), gunshot or explosion (E955; X72-X75), jumping or lying in front of a moving object (E957, E958.0; X80, X81), stabbing or blunt trauma (E956; X78, X79), vehicle collision (E958.5, E958.6; X82), electrocution (E958.4; X83), and self-immolation (E958.1; X76). Assignment of an E-code is mandatory in Canada when a diagnosis of poisoning or injury is coded.26 E-codes were provided for more than 97% of injury hospitalizations and thus are considered complete in British Columbia, contrary to most US administrative data sources.27 Studies of the validity of the deliberate self-harm E-codes used in this study have reported a positive predictive value of 86% relative to the gold standard of suicide attempts as identified by medical record review28 and good agreement between coding and expert opinion on the cause and intent of injuries.29 Suicide death certificates are also accurate relative to the gold standard of medical record review, with a sensitivity of 90% and a specificity of 100%.30

PATIENT CHARACTERISTICS

Patient characteristics were assessed at treatment initiation based on medical claims during the year preceding cohort entry. These included age, sex, calendar year of cohort entry, adjusted family income status (<Can$16 000, Can$16 000-Can$28 000, and >Can$28 000 as defined by premium subsidy levels),31 enrollment in an income assistance plan, number of acute hospitalizations, Charlson Comorbidity Index score,32 and number of distinct generic entities prescribed. Psychiatric disorders were defined as the presence of 2 outpatient diagnoses or 1 inpatient diagnosis. These included anxiety or sleep disorders, mania and bipolar disorder, attention-deficit/hyperactivity disorder, substance abuse, psychotic disorder, delirium, personality disorders, and other mental disorders (hysteria, acute reactions to stress, sexual deviations, and disturbance of emotions specific to childhood or adolescence). Additional indicators of psychiatric severity were number of psychiatric hospitalizations, number of psychiatric visits with a depression diagnosis, suicide attempt in the past year, concurrent stimulant use, and number of psychiatric drug classes (antipsychotics, benzodiazepines, and other psychotropics) used simultaneously. Concurrent stimulant use was defined as having a stimulant supply available on the antidepressant initiation date. In addition to psychiatric comorbidities, we measured a number of general medical comorbidities, including malignant neoplasms, pain requiring opiates, poisoning or drug toxic effects, injury other than poisoning, peptic ulcer disease and gastrointestinal hemorrhage, stroke and transient ischemic attack, Parkinson disease, seizure disorders, urinary incontinence, cardiovascular disease, and chronic lung disease. A complete list of covariates and their definitions is provided in eTable 2.

STATISTICAL ANALYSES

We used Cox proportional hazards regression to estimate the effect of antidepressant use on the composite outcome of attempted or completed suicide. Fluoxetine was used as the reference group for comparisons among the SSRIs, in keeping with a recent meta-analysis of antidepressant efficacy.33 For between-class comparisons, SSRIs—the most widely used class—served as the reference group. Owing to the anticipated small number of outcomes, we included all potential confounders in an exposure propensity score to control for confounding by indication.34 No variable selection was applied. After plotting and comparing the distribution of propensity scores for the patients in the exposed and reference groups, we truncated our study population to the area of overlap. To the extent that subjects with nonoverlapping propensity scores may have absolute clinical indications or contraindications for a particular treatment, a trimmed analysis removing these subjects may offer a more relevant estimate of treatment effects.35 Because relative risk estimates varied within deciles of propensity scores, we used exposure propensity score decile as a categorical variable in the Cox proportional hazards models.

In addition to constructing a propensity score including the described covariates, we constructed a high-dimensional propensity score including empirically identified covariates.36 This technique examines all dispensed drugs, recorded diagnoses, and performed procedures reported for a patient before the initiation of antidepressant therapy and identifies those codes that could potentially bias the exposure and outcome in question. All identified codes were sorted by their potential for confounding and were used to create a propensity score based on the top 500 identified variables in addition to the variables identified by us (eTable 2). This new technique has been shown to further improve adjustment for confounding.36 We consider results from this analysis to be the most completely adjusted and will base our conclusions mainly on these results.

In addition to the propensity score–adjusted analysis, we conducted a multivariate-adjusted analysis. This model was constructed using a backward selection algorithm to select covariates from the list in eTable 2 with the exclusion criteria set to 0.2 as recommended by simulation studies on variable selection in epidemiology.37 We conducted 2 subgroup analyses: one restricted to subjects without a prior suicide attempt and a second restricted to subjects who were treatment naive (defined as having no antidepressant use in the past 3 years with complete records during this period). In addition, we tested for effect measure modification by prior psychiatric hospitalization and prior suicide attempt.

In addition to the parametric analyses we have described, we plotted Kaplan-Meier curves for suicide attempt–free survival as a function of the duration of continuous use of the index antidepressant. We also created adjusted Kaplan-Meier plots by weighting each subject by the inverse of his or her probability for treatment as estimated in the propensity score analysis described earlier.

From January 1, 1997, to December 31, 2005, a total of 287 543 adults with a depression diagnosis initiated antidepressant therapy. As shown in Table 1, women accounted for 56.2% of the population. Substance abuse (2.8%), anxiety and sleep disorders (1.6%), psychotic disorder (1.6%), and other mental disorders (5.6%) were the most common psychiatric comorbidities. Among the population, 5.1% had been hospitalized for a psychiatric condition and 0.6% had a prior suicide attempt. The SSRIs were the most common class of medication prescribed, accounting for 65.5% of antidepressant use. Paroxetine and citalopram, the most commonly prescribed drugs, accounted for 39.7% and 24.2% of overall SSRI use, respectively. A total of 199 594 subjects (69.4%) had no antidepressant use in the past 3 years, composing a treatment-naive subgroup.

Table Graphic Jump LocationTable 1 Baseline Patient Characteristicsa

The mean follow-up was 0.49 person-years. A total of 89 826 subjects (31.2%) reached 1 year of follow-up; 197 681 subjects (68.8%) were censored before the end of 1 year. Antidepressant discontinuation was the most common reason for censoring (49.2%), followed by antidepressant switching or augmentation (10.6%), end of the study period (5.0%), nursing home admission (2.1%), emigration (0.8%), nonsuicide death (0.8%), and attempted suicide or suicide death (0.3%).

During the first year of antidepressant use, we identified a total of 846 adults who attempted suicide (751 adults) and/or completed suicide (104 adults), yielding an event rate of 6.06 attempted and completed suicides per 1000 person-years (95% confidence interval [CI], 5.65-6.48). The composite event rates in subgroups of treatment-naive subjects and subjects without a prior suicide attempt were similar to the overall rate (Table 2). Although the hazards were proportional throughout the 1-year follow-up period, most of the events happened in the first 6 months after initiation (Figure 1 and Figure 2). We identified a total of 155 violent suicides or suicide attempts during the follow-up period, resulting in a rate of 1.11 per 1000 person-years (95% CI, 0.94-1.30).

Place holder to copy figure label and caption
Figure 1

Probability of remaining free of suicide or suicide attempt by selective serotonin reuptake inhibitor agent and time since treatment initiation.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2

Probability of remaining free of suicide or suicide attempt by antidepressant class and time since treatment initiation. MAOIs indicates monoamine oxidase inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRIs, selective serotonin reuptake inhibitors; and TCAs, tricyclic agents.

Graphic Jump Location
Table Graphic Jump LocationTable 2 Suicide and Attempted Suicide Counts and Rates During 1-Year Follow-up

As shown in Table 3, in unadjusted analyses citalopram was associated with a reduced risk of attempted or completed suicide compared with fluoxetine among all adults (hazard ratio [HR] = 0.63; 95% CI, 0.47-0.85). This effect was attenuated to 0.86 (95% CI, 0.56-1.32) in a propensity score–adjusted analysis and to 1.00 (95% CI, 0.63-1.58) when the analysis was restricted to patients with no antidepressant use in the past 3 years. Sertra line was also associated with an apparent reduced risk in all adults in the propensity score–adjusted analysis (HR = 0.72; 95% CI, 0.53-0.99). This effect was attenuated when the population was restricted to subjects with no antidepressant use in the 3 years prior to antidepressant initiation. Venlafaxine was associated with an increased risk of attempted or completed suicide after propensity score adjustment (HR = 1.22; 95% CI, 1.00-1.49). This association was attenuated after restriction to subjects with no antidepressant use in the 3 years prior to antidepressant initiation (HR = 1.16; 95% CI, 0.92-1.47). There were no significant differences among antidepressant classes. Truncating follow-up time at 6 months yielded results quantitatively similar to our 1-year analysis (eTable 3). Propensity score–weighted Kaplan-Meier plots of pairwise comparisons with fluoxetine are presented in eFigure 1, and pairwise comparisons of other antidepressant classes are presented in eFigure 2. The lack of major differences between survival plots is consistent with our findings in Table 3. The HRs were similarly proportional over time between agents and refute meaningful differences in time to suicidal acts after initiation of drug treatment.

Table Graphic Jump LocationTable 3 Event Hazard Ratios for Composite and Violent Composite Outcomes During 1-Year Follow-up Comparing Other Selective Serotonin Reuptake Inhibitors vs Fluoxetine and Comparing Other Antidepressant Classes vs Selective Serotonin Reuptake Inhibitorsa

Citalopram appeared to be associated with a lower risk of violent suicides and suicide attempts (HR = 0.35; 95% CI, 0.16-0.77). This apparent effect was not attenuated by restriction to treatment-naive subjects or to subjects without prior suicide attempts.

We did not find evidence of effect measure modification by prior psychiatric hospitalization.

In a population of 287 543 adults aged 18 years and older initiating antidepressant therapy in British Columbia between January 1, 1997, and December 31, 2005, we observed no clinically meaningful variation in the risk of suicide and suicide attempt by the type of antidepressant initiated. Most events occurred in the first 6 months after treatment initiation. We observed some variation in the effect size between individual agents to the extent that 95% CIs were not overlapping when comparing antidepressants using conventional propensity score methods. Effect sizes became more similar after restriction to subjects without any antidepressant use in the past 3 years; this population is much closer to a population of first-time antidepressant users and an analysis within this population is less confounded by prior treatment experience and progression of the underlying condition, providing a more valid estimate of the causal treatment effects.

Our results are consistent with the findings of several other recent observational studies that reported small or no differences in suicides and suicide attempts between antidepressant classes1012 and a meta-analysis of randomized controlled trial data that found no difference in suicide attempt rates between SSRI and TCA users.38 Similar to a cohort study using General Practice Research Database data, we found a higher rate of suicidal acts in venlafaxine users compared with SSRI users, even after adjustment for measured confounders. This effect was attenuated in secondary analyses restricted to treatment-naive users, suggesting some residual confounding in our primary analysis.14 In contrast to a case-control study in Ontario residents aged 66 years and older,15 we did not observe an increased risk of violent suicide among SSRI initiators relative to initiators of other antidepressants. This same article reported that SSRIs were associated with a nearly 5-fold increased risk of suicide during the first month of treatment compared with other antidepressants but found no difference between classes during subsequent periods. While our adjusted analyses did not specifically compare suicide rates between agents during the first month of treatment, our HRs appeared to be proportional over time and we did not observe an overall increase in the risk of suicide among patients treated with SSRIs relative to patients treated with other antidepressants.

During the 9-year study period, the suicide risk among all British Columbia residents aged 18 years and older averaged around 0.16 suicide deaths per 1000 people.39,40 The rate we observed after initiation of antidepressant therapy was almost 5 times higher, reflecting the current depressed state and greater degree of psychiatric comorbidity in our population.

One of the major strengths of our study is that the large, stable study population allowed us to look at a variety of medications and at important subgroups. We had an adequate sample size to restrict our study to new initiators of antidepressants with a recorded depression diagnosis. An incident user design reduces the likelihood of missing early adverse events, allows for an evaluation of risks over time, ensures that the assessment of patient baseline characteristics is uninfluenced by any effects of antidepressant treatment, and reduces the likelihood that current treatment assignment is influenced by past drug-related experiences such as adverse effects and refractory symptoms. To have clearly identified exposure groups, we compared monotherapies with each other and censored patient follow-up as soon as the patient switched drugs or augmented therapy. This analytic strategy makes treatment groups more comparable with regard to initial health state and avoids analytic difficulties associated with comparing patients who escalate or change treatment in response to treatment failure or adverse effects vs those who do not. This will reduce the generalizability of our findings to patients receiving monotherapy, but the improvement in validity outweighs this reduction in generalizability. Similarly, we limited the follow-up time for the primary analysis to 12 months. Most events happened during that period, and longer observation would lead to increasingly selected populations in later months. Such patients would by definition not switch or discontinue their initial antidepressant for a 12-month period and their depression is likely well controlled without drug intolerance.

Nonrandomized studies using health care utilization data are particularly scrutinized for their limited control of confounding and their potential for misclassifying diagnoses.41 Confounding would occur if certain antidepressants were more likely to be given to patients with a greater background risk of suicide. We therefore controlled for sociodemographic, clinical, and health care utilization factors likely to be independent predictors of suicidality using traditional multivariate and high-dimensional propensity score techniques. Although we could show that with increasing adjustment (including high-dimensional propensity score adjustment36) point estimates generally moved closer to the null result, our ability to fully adjust for mental health status is limited by the measurement and reporting of mental health conditions as ICD-9 diagnosis codes on insurance claims to the provincial government. Well-validated behavioral risk factors such as impulsivity and hopelessness, environmental factors such as access to lethal means, and family history of completed suicide42 would not be measured in claims data. Random misclassification of confounders in health care utilization databases leads to incomplete adjustment of confounding bias.43 For example, our finding that the apparent increased risk of suicide among venlafaxine users was attenuated when we restricted our analysis to subjects with no antidepressant use in the past 3 years suggests that there may have been residual confounding by the presence of treatment-resistant depression or other suicide risk factors in our initial analysis. Other studies have documented that venlafaxine tends to be prescribed to people with past SSRI treatment failure44,45 and with a greater burden of suicide risk factors.46

There are several limitations inherent in our definition of completed and attempted suicide outcomes. It is known that suicides are underreported by coroners, with an estimated 10% of suicides misclassified as other injuries in one US study.30 However, the specificity of suicide as a cause of death has been shown to be extremely high.30 Relative risk estimates are unbiased if outcomes are assessed with 100% specificity, even if sensitivity is far lower owing to nondifferential misclassification.47 While underreporting of suicide deaths is likely nondifferential, there is a possibility that patients treated with specific agents or having specific histories might attract closer scrutiny for potential suicide. Decedents using TCAs, which are known to be fatal in overdose, might be more likely to receive a suicide diagnosis. To make our analyses comparable to those presented by Juurlink et al,15 we analyzed the sub–end point of violent completed and attempted suicide. Because there is some evidence that suicide mechanism is not coded with perfect accuracy and intent is coded with greater accuracy for injuries due to poisoning than those due to firearms29 and because of the smaller number of violent events, we place the greatest weight on our overall findings.

In terms of the validity of our suicide attempt definition, intentional self-harm E-codes do not distinguish between suicidality and self-harm without suicidal intent despite their widespread use in research and surveillance to identify suicide attempts. However, a study of the validity of deliberate self-harm E-codes to identify suicide attempts reported a positive predictive value of 86% for these codes relative to the gold standard of medical record review.28 Ascertainment of intentional self-harm admissions within the British Columbia hospital discharge database is likely to be nearly complete as this database has an E-coding completeness rate greater than 95% for the years evaluated and does not have the E-coding completeness problems documented in some US claims databases.27 However, we did not have data on suicide attempts by patients who were seen in an emergency department, treated, and released without an inpatient admission. An analysis of 2006 US Web-Based Injury Statistics Query and Reporting System48 data showed that 70% of patients with nonfatal self-harm cases seen in the emergency department were admitted to the hospital, suggesting that our definition had a 70% sensitivity for nonfatal intentional self-harm. Our inclusion of only more severe attempts that require at least 1 night in the hospital is likely to increase the specificity.

Despite these limitations, our finding of equal event rates across antidepressant agents supports the US Food and Drug Administration's decision to treat all antidepressants alike in their advisory. Treatment decisions should be based on efficacy, and clinicians should be vigilant in monitoring after initiating therapy with any antidepressant agent.

Correspondence: Sebastian Schneeweiss, MD, ScD, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont St, Ste 3030, Boston, MA 02120 (schneeweiss@post.harvard.edu).

Submitted for Publication: April 1, 2009; final revision received September 11, 2009; accepted September 23, 2009.

Author Contributions: Dr Schneeweiss had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Financial Disclosure: None reported.

Funding/Support: This work was supported by grant RO1-MH078708 from the National Institute of Mental Health.

Disclaimer: The views expressed in this article do not necessarily represent the views of the National Institute of Mental Health, the National Institutes of Health, the Department of Health and Human Services, or the US government.

Kessler  RCBerglund  PBorges  GNock  MWang  PS Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. JAMA 2005;293 (20) 2487- 2495
PubMed
Baldessarini  RJTondo  LStrombom  IMDominguez  SFawcett  JLicinio  JOquendo  MATollefson  GDValuck  RJTohen  M Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry 2007;15 (4) 133- 145
PubMed
Isacsson  GHolmgren  AOsby  UAhlner  J Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995-2005. Acta Psychiatr Scand 2009;120 (1) 37- 44
PubMed
US Food and Drug Administration Summary minutes of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee, September 13-14, 2004. http://www.fda.gov/ohrms/dockets/ac/04/minutes/2004-4065M1_Final.htm. Accessed February 1, 2005
Hammad  TALaughren  TRacoosin  J Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63 (3) 332- 339
PubMed
US Food and Drug Administration Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf. Accessed May, 2007
Gunnell  DSaperia  JAshby  D Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330 (7488) 385
PubMed
Saperia  JAshby  DGunnell  D Suicidal behaviour and SSRIs: updated meta-analysis. BMJ 2006;332 (7555) 1453
PubMed
Hammad  TALaughren  TPRacoosin  JA Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006;26 (2) 203- 207
PubMed
Jick  HKaye  JJick  S Antidepressants and the risk of suicidal behaviors. JAMA 2004;292 (3) 338- 343
PubMed
Martinez  CRietbrock  SWise  LAshby  DChick  JMoseley  JEvans  SGunnell  D Antidepressant treatment and the risk of fatal and non-fatal self-harm in first episode depression: nested case-control study. BMJ 2005;330 (7488) 389
PubMed
Simon  GESavarino  JOperskalski  BWang  PS Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163 (1) 41- 47
PubMed
Valuck  RJLibby  AMSills  MRGiese  AAAllen  RR Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004;18 (15) 1119- 1132
PubMed
Rubino  ARoskell  NTennis  PMines  DWeich  SAndrews  E Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334 (7587) 242
PubMed
Juurlink  DNMamdani  MMKopp  ARedelmeier  DA The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006;163 (5) 813- 821
PubMed
Fazel  SGrann  MAhlner  JGoodwin  G Suicides by violent means in individuals taking SSRIs and other antidepressants: a postmortem study in Sweden, 1992-2004. J Clin Psychopharmacol 2007;27 (5) 503- 506
PubMed
British Columbia Ministry of Health Services PharmaNet. http://www.health.gov.bc.ca/pharmacare/pharmanet/netindex.html. Accessed October 17, 2008
Williams  JIYoung  W Inventory of Studies on the Accuracy of Canadian Health Administrative Databases.  Toronto, ON: Institute for Clinical Evaluative Sciences; 1996
Pharmaceutical Services Division, Ministry of Health Services, Government of British Columbia BC PharmaCare Annual Performance Report 2005. http://www.health.gov.bc.ca/pharmacare/pdf/APROnline.pdf. Accessed October 17, 2008
Dormuth  CRGlynn  RJNeumann  PMaclure  MBrookhart  AMSchneeweiss  S Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther2006286964978, discussion 962-963
PubMed
Dormuth  CRSchneeweiss  SBrookhart  MACarney  GBassett  KAdams  SWright  JM Frequency and predictors of tablet splitting in statin prescriptions: a population-based analysis. Open Med 2008;2 (3) e5- e13
Kwon  ABungay  KMPei  YRogers  WHWilson  IBZhou  QAdler  DA Antidepressant use: concordance between self-report and claims records. Med Care 2003;41 (3) 368- 374
PubMed
Johnson  REVollmer  WM Comparing sources of drug data about the elderly. J Am Geriatr Soc 1991;39 (11) 1079- 1084
PubMed
World Health Organization International Classification of Diseases, Ninth Revision (ICD-9).  Geneva, Switzerland: World Health Organization; 1977
World Health Organization International Statistical Classification of Diseases, 10th Revision (ICD-10).  Geneva, Switzerland: World Health Organization; 1992
Canadian Institute for Health Information Abstracting Manual.  Ottawa, ON: Canadian Institute for Health Information; 1999
Clark  DEDeLorenzo  MALucas  FLWennberg  DE Epidemiology and short-term outcomes of injured Medicare patients. J Am Geriatr Soc 2004;52 (12) 2023- 2030
PubMed
Iribarren  CSidney  SJacobs  DR  JrWeisner  C Hospitalization for suicide attempt and completed suicide: epidemiological features in a managed care population. Soc Psychiatry Psychiatr Epidemiol 2000;35 (7) 288- 296
PubMed
LeMier  MCummings  PWest  TA Accuracy of external cause of injury codes reported in Washington State hospital discharge records. Inj Prev 2001;7 (4) 334- 338
PubMed
Moyer  LABoyle  CAPollock  DA Validity of death certificates for injury-related causes of death. Am J Epidemiol 1989;130 (5) 1024- 1032
PubMed
Warburton  RN Takeup of income-tested health-care premium subsidies: evidence and remedies for British Columbia. Can Tax J 2005;53 (1) 1- 28
Charlson  MEPompei  PAles  KLMacKenzie  CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40 (5) 373- 383
PubMed
Cipriani  AFurukawa  TASalanti  GGeddes  JRHiggins  JPChurchill  RWatanabe  NNakagawa  AOmori  IMMcGuire  HTansella  MBarbui  C Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373 (9665) 746- 758
PubMed
Braitman  LERosenbaum  PR Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002;137 (8) 693- 695
PubMed
Schneeweiss  SPatrick  ARStürmer  TBrookhart  MAAvorn  JMaclure  MRothman  KJGlynn  RJ Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007;45 (10 (suppl 2)) S131- S142
PubMed
Schneeweiss  SRassen  JAGlynn  RJAvorn  JMogun  HBrookhart  MA High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20 (4) 512- 522
PubMed
Maldonado  GGreenland  S Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138 (11) 923- 936
PubMed
Fergusson  DDoucette  SGlass  KCShapiro  SHealy  DHebert  PHutton  B Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials [published correction appears in BMJ. 2005;330(7492):653]. BMJ 2005;330 (7488) 396
PubMed
British Columbia Coroners Service Suicide statistics, 1997-2004. http://www.pssg.gov.bc.ca/coroners/publications/docs/stats-suicide-1997-2004.pdf. Accessed November 18, 2008
BCStats British Columbia population by selected age groups. http://www.bcstats.gov.bc.ca/data/pop/pop/project/bc0806tab3.csv. Accessed November 18, 2008
Schneeweiss  SAvorn  J A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58 (4) 323- 337
PubMed
Hawton  Kvan Heeringen  K Suicide. Lancet 2009;373 (9672) 1372- 1381
PubMed
Greenland  SRobins  J Confounding and misclassification. Am J Epidemiol 1985;122 (3) 495- 506
PubMed
Stahl  SMGrady  MMMoret  CBriley  M SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10 (9) 732- 747
PubMed
Rush  AJTrivedi  MHWisniewski  SRStewart  JWNierenberg  AAThase  MERitz  LBiggs  MMWarden  DLuther  JFShores-Wilson  KNiederehe  GFava  MSTAR*D Study Team, Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354 (12) 1231- 1242
PubMed
Mines  DHill  DYu  HNovelli  L Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 2005;14 (6) 367- 372
PubMed
Kelsey  JLWhittemore  ASEvans  ASThompson  WD Methods in Observational Epidemiology. 2nd ed. New York, NY: Oxford University Press; 1996
Centers for Disease Control and Prevention Web-Based Injury Statistics Query and Reporting System (WISQARS), 2006. http://www.cdc.gov/ncipc/wisqars. Accessed February 12, 2008

Figures

Place holder to copy figure label and caption
Figure 1

Probability of remaining free of suicide or suicide attempt by selective serotonin reuptake inhibitor agent and time since treatment initiation.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2

Probability of remaining free of suicide or suicide attempt by antidepressant class and time since treatment initiation. MAOIs indicates monoamine oxidase inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRIs, selective serotonin reuptake inhibitors; and TCAs, tricyclic agents.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1 Baseline Patient Characteristicsa
Table Graphic Jump LocationTable 2 Suicide and Attempted Suicide Counts and Rates During 1-Year Follow-up
Table Graphic Jump LocationTable 3 Event Hazard Ratios for Composite and Violent Composite Outcomes During 1-Year Follow-up Comparing Other Selective Serotonin Reuptake Inhibitors vs Fluoxetine and Comparing Other Antidepressant Classes vs Selective Serotonin Reuptake Inhibitorsa

References

Kessler  RCBerglund  PBorges  GNock  MWang  PS Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. JAMA 2005;293 (20) 2487- 2495
PubMed
Baldessarini  RJTondo  LStrombom  IMDominguez  SFawcett  JLicinio  JOquendo  MATollefson  GDValuck  RJTohen  M Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry 2007;15 (4) 133- 145
PubMed
Isacsson  GHolmgren  AOsby  UAhlner  J Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995-2005. Acta Psychiatr Scand 2009;120 (1) 37- 44
PubMed
US Food and Drug Administration Summary minutes of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee, September 13-14, 2004. http://www.fda.gov/ohrms/dockets/ac/04/minutes/2004-4065M1_Final.htm. Accessed February 1, 2005
Hammad  TALaughren  TRacoosin  J Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63 (3) 332- 339
PubMed
US Food and Drug Administration Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC). http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf. Accessed May, 2007
Gunnell  DSaperia  JAshby  D Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330 (7488) 385
PubMed
Saperia  JAshby  DGunnell  D Suicidal behaviour and SSRIs: updated meta-analysis. BMJ 2006;332 (7555) 1453
PubMed
Hammad  TALaughren  TPRacoosin  JA Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006;26 (2) 203- 207
PubMed
Jick  HKaye  JJick  S Antidepressants and the risk of suicidal behaviors. JAMA 2004;292 (3) 338- 343
PubMed
Martinez  CRietbrock  SWise  LAshby  DChick  JMoseley  JEvans  SGunnell  D Antidepressant treatment and the risk of fatal and non-fatal self-harm in first episode depression: nested case-control study. BMJ 2005;330 (7488) 389
PubMed
Simon  GESavarino  JOperskalski  BWang  PS Suicide risk during antidepressant treatment. Am J Psychiatry 2006;163 (1) 41- 47
PubMed
Valuck  RJLibby  AMSills  MRGiese  AAAllen  RR Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004;18 (15) 1119- 1132
PubMed
Rubino  ARoskell  NTennis  PMines  DWeich  SAndrews  E Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334 (7587) 242
PubMed
Juurlink  DNMamdani  MMKopp  ARedelmeier  DA The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006;163 (5) 813- 821
PubMed
Fazel  SGrann  MAhlner  JGoodwin  G Suicides by violent means in individuals taking SSRIs and other antidepressants: a postmortem study in Sweden, 1992-2004. J Clin Psychopharmacol 2007;27 (5) 503- 506
PubMed
British Columbia Ministry of Health Services PharmaNet. http://www.health.gov.bc.ca/pharmacare/pharmanet/netindex.html. Accessed October 17, 2008
Williams  JIYoung  W Inventory of Studies on the Accuracy of Canadian Health Administrative Databases.  Toronto, ON: Institute for Clinical Evaluative Sciences; 1996
Pharmaceutical Services Division, Ministry of Health Services, Government of British Columbia BC PharmaCare Annual Performance Report 2005. http://www.health.gov.bc.ca/pharmacare/pdf/APROnline.pdf. Accessed October 17, 2008
Dormuth  CRGlynn  RJNeumann  PMaclure  MBrookhart  AMSchneeweiss  S Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther2006286964978, discussion 962-963
PubMed
Dormuth  CRSchneeweiss  SBrookhart  MACarney  GBassett  KAdams  SWright  JM Frequency and predictors of tablet splitting in statin prescriptions: a population-based analysis. Open Med 2008;2 (3) e5- e13
Kwon  ABungay  KMPei  YRogers  WHWilson  IBZhou  QAdler  DA Antidepressant use: concordance between self-report and claims records. Med Care 2003;41 (3) 368- 374
PubMed
Johnson  REVollmer  WM Comparing sources of drug data about the elderly. J Am Geriatr Soc 1991;39 (11) 1079- 1084
PubMed
World Health Organization International Classification of Diseases, Ninth Revision (ICD-9).  Geneva, Switzerland: World Health Organization; 1977
World Health Organization International Statistical Classification of Diseases, 10th Revision (ICD-10).  Geneva, Switzerland: World Health Organization; 1992
Canadian Institute for Health Information Abstracting Manual.  Ottawa, ON: Canadian Institute for Health Information; 1999
Clark  DEDeLorenzo  MALucas  FLWennberg  DE Epidemiology and short-term outcomes of injured Medicare patients. J Am Geriatr Soc 2004;52 (12) 2023- 2030
PubMed
Iribarren  CSidney  SJacobs  DR  JrWeisner  C Hospitalization for suicide attempt and completed suicide: epidemiological features in a managed care population. Soc Psychiatry Psychiatr Epidemiol 2000;35 (7) 288- 296
PubMed
LeMier  MCummings  PWest  TA Accuracy of external cause of injury codes reported in Washington State hospital discharge records. Inj Prev 2001;7 (4) 334- 338
PubMed
Moyer  LABoyle  CAPollock  DA Validity of death certificates for injury-related causes of death. Am J Epidemiol 1989;130 (5) 1024- 1032
PubMed
Warburton  RN Takeup of income-tested health-care premium subsidies: evidence and remedies for British Columbia. Can Tax J 2005;53 (1) 1- 28
Charlson  MEPompei  PAles  KLMacKenzie  CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40 (5) 373- 383
PubMed
Cipriani  AFurukawa  TASalanti  GGeddes  JRHiggins  JPChurchill  RWatanabe  NNakagawa  AOmori  IMMcGuire  HTansella  MBarbui  C Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373 (9665) 746- 758
PubMed
Braitman  LERosenbaum  PR Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002;137 (8) 693- 695
PubMed
Schneeweiss  SPatrick  ARStürmer  TBrookhart  MAAvorn  JMaclure  MRothman  KJGlynn  RJ Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007;45 (10 (suppl 2)) S131- S142
PubMed
Schneeweiss  SRassen  JAGlynn  RJAvorn  JMogun  HBrookhart  MA High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20 (4) 512- 522
PubMed
Maldonado  GGreenland  S Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138 (11) 923- 936
PubMed
Fergusson  DDoucette  SGlass  KCShapiro  SHealy  DHebert  PHutton  B Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials [published correction appears in BMJ. 2005;330(7492):653]. BMJ 2005;330 (7488) 396
PubMed
British Columbia Coroners Service Suicide statistics, 1997-2004. http://www.pssg.gov.bc.ca/coroners/publications/docs/stats-suicide-1997-2004.pdf. Accessed November 18, 2008
BCStats British Columbia population by selected age groups. http://www.bcstats.gov.bc.ca/data/pop/pop/project/bc0806tab3.csv. Accessed November 18, 2008
Schneeweiss  SAvorn  J A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58 (4) 323- 337
PubMed
Hawton  Kvan Heeringen  K Suicide. Lancet 2009;373 (9672) 1372- 1381
PubMed
Greenland  SRobins  J Confounding and misclassification. Am J Epidemiol 1985;122 (3) 495- 506
PubMed
Stahl  SMGrady  MMMoret  CBriley  M SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10 (9) 732- 747
PubMed
Rush  AJTrivedi  MHWisniewski  SRStewart  JWNierenberg  AAThase  MERitz  LBiggs  MMWarden  DLuther  JFShores-Wilson  KNiederehe  GFava  MSTAR*D Study Team, Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354 (12) 1231- 1242
PubMed
Mines  DHill  DYu  HNovelli  L Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 2005;14 (6) 367- 372
PubMed
Kelsey  JLWhittemore  ASEvans  ASThompson  WD Methods in Observational Epidemiology. 2nd ed. New York, NY: Oxford University Press; 1996
Centers for Disease Control and Prevention Web-Based Injury Statistics Query and Reporting System (WISQARS), 2006. http://www.cdc.gov/ncipc/wisqars. Accessed February 12, 2008

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment
VARIATION IN THE RISK OF SUICIDE BY ANTIDEPRESSANT AGENT IN ADULTS
Posted on July 8, 2010
John R. Geddes, MD
University of Oxford
Conflict of Interest: None Declared
In their cohort study of a population of 287 543 adults aged 18 years and older initiating antidepressant therapy in British Columbia between January 1997 and December 2005, Schneeweiss and colleagues reported that they observed no clinically meaningful variation in the risk of suicide and suicide attempt by the type of antidepressant initiated (Schneeweiss et al., 2010). However, it should be noted that the authors did observe some variation in the effect size between individual agents when comparing antidepressants using conventional propensity score methods. Adjustment using propensity scores aims to reduce the potential for confounding by indication – which occurs when prognostically important baseline patient characteristics influence choice of treatment and lead to apparent, but spurious, differences between treatments (Braitman et al., 2002). Although relying on routinely collected data, observational studies such as this can offer insights into long term and real world outcomes for large groups of people, but these studies are prone to selection biases and may have limited power to detect moderate, but clinically important, differences between agents. In drawing conclusions of causality it is therefore important to consider both the precision of the estimates of comparative risk and additional randomized evidence on antidepressants in psychiatric disorders, like major depression.
This study had limited precision producing wide confidence intervals. It is simply erroneous to conclude that lack of statistical significance is the same as absence of evidence (Altman & Bland, 1995). Several of the point estimates were entirely consistent with a recent meta-analysis of individual patient data from placebo controlled randomized trials in adults with psychiatric disorders of the association between risk of suicide and antidepressants which found a small statistically significant decrease in risk with some antidepressants (i.e. sertraline, risk difference/1000 -2.50, 95% CI -4.99 to -0.01, , P=0.05) and not with other selective serotonin reuptake inhibitors, tricyclics or newer antidepressants (Stone et al., 2009). Contrary to the conclusions of the authors, therefore, we would interpret the totality of the evidence as indicating that there may in fact be clinically meaningful differences between agents in their propensity to induce suicidal behaviour. In particular, sertraline appears to be consistently less likely to induce suicidal behaviour. Coupled with the evidence of superior efficacy and acceptability (Cipriani et al., 2009), this would suggest that this drug has a relatively favourable clinical profile.
John Geddes, MD Corrado Barbui, MD Andrea Cipriani, MD PhD
Author Affiliations: Department of Psychiatry, University of Oxford, UK (Professor Geddes); and Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology, University of Verona, Italy (Drs Cipriani and Barbui). Correspondence: Prof John R Geddes, Oxford; Clinical Trials Unit for Mental Illness, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK (john.geddes@psych.ox.ac.uk)
Financial Disclosure: None (Drs Cipriani and Barbui); Professor Geddes has received research funding from the Medical Research Council, Economic and Social Research Council, National Institute for Health Research, and the Stanley Medical Research Institute and has received donations of drugs supplies for trials from Sanofi-Aventis and GlaxoSmithKline. He has acted as an expert witness for Dr Reddys.
References
1. Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, Lee JC, Wang PS. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score- adjusted analysis of 9 years' data. Arch Gen Psychiatry. 2010;67:497-506.
2. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med. 2002;137(8):693-695.
3. Stone MB, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:b2880.
4. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995; 311: 485.
5. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373: 746-58.
Suicide Causality
Posted on August 2, 2010
Donald F. Klein, MD DSc
NYU Dept Child Adolescent Psychiatry
Conflict of Interest: None Declared
Schneeweiss et al reviewing naturalistic data cannot find differences in hospitalizations from suicide attempts or mortality among the various antidepressants. Therefore, they affirm that the FDA was correct in its class wide Black Box warnings. Geddes et al assert that these contrasts were too low power to assert equivalence but believe that sertraline has the best overall track record. It should be emphasized that neither study can speak clearly to causality given the confounding suicidal propensities of severe depression. In the placebo controlled trials that instigated the FDA warnings there were no completed suicides. The suicidality index used has never demonstrated predictive validity. We entirely agree that depressed patients requiring medication, as well as those who do not, warrant careful, frequent, monitoring. However, the data referred to above are heuristically irrelevant. That they have been used to scare depressed patients away from indicated treatment seems counterproductive. Large scale lengthy placebo controlled trials lack feasibility. However, properly cross-linked outpatient, hospital, postmortem, prescriptive records can afford a firmer basis for such inferences, as Klein and O'Brien have discussed in JAMA, July 18, 2007—Vol 298, No. 3. However the current administration's plans are only a short step toward this goal. Nonetheless, advanced pharmacovigilance programs already exist in Europe and can serve as a model.

Conflict of Interest: None declared
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles